Motolimod, TLR8 Agonist (TBI4920)

Description

Product Details

Formal Name: 2-Amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzapine-4-carboxamide

Alternate Names: VTX-2337

Molecular Formula: C₂₈H₃₄N₄O₂

Formula Weight: 458.61

CAS Number: 926927-61-9

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to at least 25 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.

 

Applications

TLR8 Agonist

 

Functions

Motolimod (926927-61-9) is a selective Toll-like receptor 8 (TLR8) agonist (EC50 = 100 nM). It stimulates the production of TNFα and IL-12 from monocytes and myeloid dendritic cells. Motolimod also stimulated IFNγ production from NK cells and increased their toxicity against K562 and ADCC by rituximab and trastuzumab. It induced apoptosis in monocytic myeloid-derived suppressor cells. Motolimod is being investigated in combination with other cancer immunotherapies. Motolimod has also been shown in induce secreted IL-1b and IL-8 via activation of the NLRP3 inflammasome.

 

Application Procedures

First dissolved in DMSO (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

Additional information

SIZE (mg)	25 MG, 5 MG

Datasheet:

TBI4920_Motolimod

MSDS:

TBI4920_Motolimod_MSDS_2024